环孢素A对高危角膜移植术患者房水炎症因子影响及临床效果研究

发布时间：2017-12-26 17:09

本文关键词：环孢素A对高危角膜移植术患者房水炎症因子影响及临床效果研究　出处：《临床眼科杂志》2016年03期 　论文类型：期刊论文

【摘要】：目的探讨环孢素A对高危角膜移植术患者房水炎症因子影响及临床效果,为高危角膜移植术患者治疗和预后提供参考。方法分析2013年1月至2014年8月52例在我院行穿透性角膜移植(PKP)患者的临床资料,对照组采用地塞米松滴眼液进行治疗,观察组在对照组治疗的基础上给予环孢素A滴眼液滴眼治疗,并比较两组患者房水中炎症因子、VEGF水平改变及治疗效果。结果治疗后观察组房水中TNF-α(t=2.885,P=0.006)、IL-2(t=2.386,P=0.021)、IL-6(t=2.961,P=0.005)、治疗总有效率(χ~2=5.223,P=0.022)水平明显高于对照组,差异均具有统计学意义(P0.05);对照组患者不良反应发生率(χ~2=6.504,P=0.011)、VEGF(t=7.370,P0.001)明显高于观察组,差异具有统计学意义(P0.05)。经过Log-rank检验后发现,观察组患者免疫排斥反应率明显低于对照组,差异具有统计学意义(1,3.57%vs 6,25%;Log-rankχ~2=4.593,P=0.032)。结论环孢素A能够抑制高危角膜移植患者术后细胞因子的释放和新生血管的形成,可进一步提高PKP的治疗效果和降低排斥反应的发生,临床治疗安全性较好,可以在临床治疗上加以推广。
[Abstract]:Objective to investigate the effect of cyclosporine A on the inflammatory factors in aqueous humor of high-risk corneal allograft recipients, and to provide references for the treatment and prognosis of high-risk keratoplasty patients. Methods from January 2013 to August 2014 of 52 cases in our hospital underwent penetrating keratoplasty (PKP) clinical data of the patients in control group were treated with dexamethasone eyedrops for treatment, the observation group was treated with cyclosporin A eyedrops in the treatment based on the treatment in control group, and compared between the two groups in aqueous humor of patients with inflammatory factors, the level of VEGF change and effect of treatment. Results after treatment, the observation group of real water TNF- alpha (t=2.885, P=0.006), IL-2 (t=2.386, P=0.021), IL-6 (t=2.961, P=0.005), the total efficiency of treatment (~2=5.223, P=0.022) was significantly higher than the control group, the differences were statistically significant (P0.05); the incidence of adverse reaction in control group patients (x2 ~2=6.504, P=0.011, VEGF) (t=7.370, P0.001) was significantly higher than the observation group, the difference was statistically significant (P0.05). After Log-rank test, it was found that the immunological rejection rate in the observation group was significantly lower than that in the control group, the difference was statistically significant (1,3.57%vs 6,25%; Log-rank x ~2=4.593, P=0.032). Conclusion cyclosporine A can inhibit the release of cytokines and the formation of neovascularization after high risk keratoplasty. It can further improve the therapeutic effect of PKP and reduce the occurrence of rejection. The clinical treatment is safe and can be promoted in clinical treatment.
【作者单位】：四川省林业中心医院眼科;四川大学华西第四医院眼科;
【分类号】：R779.65
【正文快照】： 作者单位:610081成都,四川省林业中心医院眼科(李福强、熊雅红);四川大学华西第四医院眼科(李宇)[临床眼科杂志,2016,24:203][J Clin Ophthalmol,2016,24:203]穿透性角膜移植术(penetrating keratoplasty,PKP)是用透明的角膜代替已经患者已经全层混浊的角膜的一种异体移植的手

【相似文献】